全文获取类型
收费全文 | 1632篇 |
免费 | 80篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 22篇 |
妇产科学 | 15篇 |
基础医学 | 253篇 |
口腔科学 | 18篇 |
临床医学 | 134篇 |
内科学 | 289篇 |
皮肤病学 | 19篇 |
神经病学 | 100篇 |
特种医学 | 190篇 |
外科学 | 143篇 |
综合类 | 33篇 |
预防医学 | 41篇 |
眼科学 | 19篇 |
药学 | 277篇 |
中国医学 | 44篇 |
肿瘤学 | 122篇 |
出版年
2023年 | 7篇 |
2022年 | 17篇 |
2021年 | 56篇 |
2020年 | 16篇 |
2019年 | 29篇 |
2018年 | 28篇 |
2017年 | 28篇 |
2016年 | 46篇 |
2015年 | 70篇 |
2014年 | 80篇 |
2013年 | 93篇 |
2012年 | 126篇 |
2011年 | 113篇 |
2010年 | 74篇 |
2009年 | 61篇 |
2008年 | 92篇 |
2007年 | 116篇 |
2006年 | 103篇 |
2005年 | 103篇 |
2004年 | 60篇 |
2003年 | 70篇 |
2002年 | 47篇 |
2001年 | 22篇 |
2000年 | 17篇 |
1999年 | 19篇 |
1998年 | 37篇 |
1997年 | 40篇 |
1996年 | 20篇 |
1995年 | 16篇 |
1994年 | 27篇 |
1993年 | 13篇 |
1992年 | 10篇 |
1991年 | 7篇 |
1990年 | 11篇 |
1989年 | 14篇 |
1988年 | 9篇 |
1987年 | 5篇 |
1986年 | 8篇 |
1985年 | 6篇 |
1984年 | 1篇 |
1983年 | 3篇 |
1982年 | 1篇 |
1981年 | 6篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1977年 | 4篇 |
1975年 | 1篇 |
排序方式: 共有1736条查询结果,搜索用时 15 毫秒
21.
Gwi Eon Kim Yong Bae Kim Nam Hoon Cho Hyun-Cheol Chung Hong Ryull Pyo Jong Doo Lee Tchan Kyu Park Woong Sub Koom Mison Chun Chang Ok Suh 《Clinical cancer research》2004,10(4):1366-1374
PURPOSE: To evaluate the potential of the new prognostic information gained by analyzing the coexpression of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) in cervical cancer patients. EXPERIMENTAL DESIGN: Sixty-eight patients with International Federation of Gynecology and Obstetrics stage IIB squamous cell carcinoma of the uterine cervix, who underwent concurrent chemoradiotherapy between 1993 and 1996, were divided into the following four groups according to their immunoreactivities for EGFR and COX-2 in paraffin-embedded sections: (a). the EGFR-negative/COX-2-negative group (n = 11); (b). the EGFR-negative/COX-2-positive group (n = 8); (c). the EGFR-positive/COX-2-negative group (n = 27); and (d). the EGFR-positive/COX-2-positive group (n = 22). The clinical features, patterns of treatment failure, and survival data in the four groups were compared. RESULTS: Positive immunoreactivity for EGFR and COX-2 was observed in 49 of 68 (72%) and 19 of 68 (28%), respectively. However, no strong correlation was found between the levels of EGFR and COX-2 immunopositivity (R(2) = 0.05, P = 0.07). Patients in the EGFR-positive/COX-2-positive group had a higher likelihood of locoregional recurrence than those in the other three groups (P = 0.02). Of the patients in the four groups, patients positive for both oncoproteins were found to have the worst prognosis with an overall 5-year disease-free survival rate of 55% compared with 91% for the EGFR-negative/COX-2-negative patients, 88% for the EGFR-negative/COX-2-positive patients, and 69% for the EGFR-positive/COX-2-negative patients (P = 0.05, log-rank test). In addition, the synchronous coexpression of the EGFR and COX-2 oncoproteins was found to be an independent prognostic factor by univariate and multivariate analyses (relative risk = 4.0, P = 0.03). CONCLUSIONS: Given these observations, we conclude that the coexpression of EGFR and COX-2 immunoreactivity may be used as a potent molecular risk factor for predicting the poor survival of patients with the International Federation of Gynecology and Obstetrics stage IIB squamous cell carcinoma of the uterine cervix. 相似文献
22.
23.
Han JY; Kim HK; Choi BG; Moon H; Hong YS; Lee KS 《Japanese journal of clinical oncology》1998,28(12):749-753
BACKGROUND: Quality of life (QOL) assessment has emerged to measure and
quantify the balance between treatment benefit and toxicity, and has a
value in predicting response and overall survival in cancer patients.
METHODS: From July 1995 to February 1997, 38 symptomatic patients with
advanced non-small cell lung cancer (NSCLC) were treated with MIP
chemotherapy (mitomycin 6 mg/m2, ifosfamide 3000 mg/m2 and cisplatin 50
mg/m2 on day 1 every 3 weeks). Patients were assessed for QOL including
physical well-being, general symptoms and lung cancer-specific symptoms, as
well as objective response. RESULTS: The overall response rate was 38.9%
(14/36, all were partial response) and the median duration of response was
3.5 months [95% confidence interval (CI) 2.0-4.0]. The median duration of
overall survival was 7 months (95% CI 5.9-8.5). The overall improvement of
QOL was 58.3% with 21 patients feeling better on treatment. The toxicity of
chemotherapy was mild, mainly nausea/vomiting and minimal alopecia. Using
multiple clinical predictors of survival (age, histology, stage,
performance status), only change of QOL emerged significantly (P = 0.0007).
CONCLUSIONS: MIP had an endurable response and low toxicity profile, and
provided good QOL. Integral QOL data in our study provided the strong
prediction of survival in advanced NSCLC. Further experienced QOL study
will provide greatly enhanced outcome data in clinical trials.
相似文献
24.
25.
26.
27.
28.
29.
30.
Travis WD Hunninghake G King TE Lynch DA Colby TV Galvin JR Brown KK Chung MP Cordier JF du Bois RM Flaherty KR Franks TJ Hansell DM Hartman TE Kazerooni EA Kim DS Kitaichi M Koyama T Martinez FJ Nagai S Midthun DE Müller NL Nicholson AG Raghu G Selman M Wells A 《American journal of respiratory and critical care medicine》2008,177(12):1338-1347